These links are provided as a convenience and is not an endorsement by Allena Pharmaceuticals of the site's content. Allena does not review or control the content of non-Allena websites.
Evaluate the Safety and Efficacy of ALLN-177 in Patients with Enteric Hyperoxaluria (uriROX-1). Nigewar S et al. ASN Kidney Week 2018.
Results of a Phase 2 Randomized Controlled Trial of ALLN-177 in Patients wth Secondary Hyperoxaluria. Nigwekar S. ASN Kidney Week 2017.
ALLN-177, a Novel Oral Enzyme Therapy, Reduces Urinary Oxalate Excretion and Plasma Oxalate in a Porcine Dietary Model of Severe Hyperoxaluria. Grujic D et al. ASN Kidney Week 2017.
A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme. Langman CB et al. Am J Nephrol 2016.
ALLN-177 Reduces Hyperoxaluria in a Porcine Model of Secondary Hyperoxaluria (2°HO) Induced by a Human-like Oxalate Rich Diet. Grujic D et al. J Urol 2016.
Hyperoxaluria Is Reduced and Nephrocalcinosis Prevented with an Oxalate-Degrading Enzyme in Mice with Hyperoxaluria. Grujic D et al. Am J Nephrol 2009.
Hypereoxaluria and Kidney Disorders
Unmet Need in Enteric Hyperoxaluria: Clinical Characteristics and Stone Burden in Patients from ALLN-177 Studies. Nigwekar S et al. ASN Kidney Week 2018.
The Cause of Idiopathic Calcium Stone Disease: Hypercalciuria or Hyperoxaluria? Robertson WG, Peacock M. Nephron 1980.
Comparison of Two Diets for the Prevention of Recurrent Stones in Idiopathic Hypercalciuria. Borghi L et al. N Engl J Med 2002.
The Most Important Metabolic Risk Factors in Recurrent Urinary Stone Formers. Parvin M et al. Urol J 2011.
24-h Uric Acid Excretion and the Risk of Kidney Stones. Curhan GC et al. Kidney Int 2008.
Results of Long-term Treatment with Orthophosphate and Pyridoxine in Patients with Primary Hyperoxaluria. Milliner DS et al. N Engl J Med 1994.
Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure. Zhao F et al. Clin J Am Soc Nephrol 2016.
Risk of Nephrolithiasis, Hyperoxaluria, and Calcium Oxalate Supersaturation Increased after Roux-en-Y Gastric Bypass Surgery: A Systematic Review and Meta-analysis. Upala S et al. Surg Obes Relat Dis 2016.
Enteric Hyperoxaluria: An Important Cause of End-stage Kidney Disease. Nazzal L et al. Nephrol Dial Transplant 2016.
Enteric Hyperoxaluria in Chronic Pancreatitis. Demoulin N et al. Medicine 2017.
Oxalate Nephropathy Complicating Roux-en-Y Gastric Bypass: An Underrecognized Cause of Irreversible Renal Failure. Nasr S et al. Clin J Am Soc Nephrol 2008.
Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. Pernipam M et al. Clin Biochem 2017.
Treatment of the Primary Hyperoxalurias: A New Chapter. Milliner, D. Kidney Int 2006.
A Novel Recombinant Oral Urate Oxidase (UrOx) ALLN-346 Reduces Severe Hyperuricemia and Normalized Hyperuricosuria in Nephropathic UrOX Knockout (UrOxKO) Mice Grujic D et al. ACR 2018
Primary and Secondary Hyperoxaluria: Understanding the Enigma. Bhasin B et al. World J Nephrol 2015.
Prevalence of Hyperoxaluria in Urinary Stone Formers: Chronological and Geographic Trends and a Literature Review. Spradling K et al. J Endourol 2016.
Oxalate, Inflammasome and Progression of Kidney Disease. Ermer T et al. Curr Opin Nephro Hypertens 2016.